![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Abstract
Genotype-based dosing recommendations are provided in the US FDA-approved warfarin labeling. However, data that informed these recommendations were from predominately Caucasian populations. Studies show that variants contributing to warfarin dose requirements in Caucasians provide similar contributions to dose requirements in US Hispanics, but significantly lesser contributions in African–Americans. Further data demonstrate that variants occurring commonly in individuals of African ancestry, but rarely in other racial groups, significantly influence dose requirements in African–Americans. These data suggest that it is important to consider variants specific for African–Americans when implementing genotype-guided warfarin dosing in this population.
Financial & competing interests disclosure
LH Cavallari has received an American Heart Association, Midwest Affiliate Grant-In-Aid (10GRNT3750024) and MA Perera has received NIH NHLBI awards (1 K23 HL089808-01A2 and HL106097). LH Cavallari is the coinvestor on the patent, CYP2C9*8 alleles correlate with decreased warfarin metabolism and increased warfarin sensitivity. US Utility Patent Application No 12/572,908. International Application No. PCT/US09/59413. Filed: 2 October 2009; Published: 27 May 2010; Pub. No. US 2010/0130599. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
No writing assistance was utilized in the production of this manuscript.